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Steven L. Walker,11,12 Yang Shi,3 James F. Gusella,1 and Lawrence C. Layman11,12,*
CHARGE syndrome and Kallmann syndrome (KS) are two distinct developmental disorders sharing overlapping features of impaired
olfaction and hypogonadism. KS is a genetically heterogeneous disorder consisting of idiopathic hypogonadotropic hypogonadism
(IHH) and anosmia, and is most commonly due to KAL1 or FGFR1mutations. CHARGE syndrome, a multisystem autosomal-dominant
disorder, is caused by CHD7 mutations. We hypothesized that CHD7 would be involved in the pathogenesis of IHH and KS (IHH/KS)
without the CHARGE phenotype and that IHH/KS represents a milder allelic variant of CHARGE syndrome. Mutation screening of
the 37 protein-coding exons of CHD7 was performed in 101 IHH/KS patients without a CHARGE phenotype. In an additional 96
IHH/KS patients, exons 6–10, encoding the conserved chromodomains, were sequenced. RT-PCR, SIFT, protein-structure analysis,
and in situ hybridization were performed for additional supportive evidence. Seven heterozygous mutations, two splice and ﬁve
missense, which were absent inR 180 controls, were identiﬁed in three sporadic KS and four sporadic normosmic IHH patients. Three
mutations affect chromodomains critical for proper CHD7 function in chromatin remodeling and transcriptional regulation, whereas
the other four affect conserved residues, suggesting that they are deleterious. CHD7’s role is further corroborated by speciﬁc expression
in IHH/KS-relevant tissues and appropriate developmental expression. SporadicCHD7mutations occur in 6% of IHH/KS patients. CHD7
represents the ﬁrst identiﬁed chromatin-remodeling protein with a role in human puberty and the second gene to cause both normos-
mic IHH and KS in humans. Our ﬁndings indicate that both normosmic IHH and KS are mild allelic variants of CHARGE syndrome and
are caused by CHD7 mutations.Idiopathic hypogonadotropic hypogonadism (IHH, MIM
146110), one of the most commonly inherited forms of
hypogonadism, results from deﬁcient hypothalamic
GnRH release or action.1 IHH patients present with absent
or impaired sexual development due to sex-steroid-hor-
mone deﬁciency, low serum levels of the pituitary gonado-
tropins follicle-stimulating hormone (FSH) and luteinizing
hormone (LH), and infertility.1 Kallmann syndrome (KS,
MIM 308700, 147950, 244200, 610628), which couples
IHH with the inability to smell (anosmia), is due to impair-
ment of the normal embryologic migration of GnRH and
olfactory neurons from the olfactory placode region into
the hypothalamus.1,2 KS patients may have additional
phenotypic abnormalities including cleft lip and palate,
unilateral renal agenesis, dental agenesis, and neurologic
abnormalities such as synkinesia and cerebellar dysfunc-tion.2 The molecular basis of IHH and KS (IHH/KS) has
been identiﬁed for approximately 25%–30% of patients,
with mutations in the KAL1 (MIM 308700),3,4 FGFR1
(MIM 136350),5–7 and GNRHR (MIM 138850)8,9 genes
being most common. A variety of other genes also cause
IHH/KS in some patients, including GPR54 (MIM
604161),10 NR0B1 (MIM 300473),11 PROKR2 (MIM
607123),12 PROK2 (MIM 607002),12 LEP (MIM 164160),2
and LEPR (MIM 601007).2 A digenic inheritance pattern
has been reported in two cases.13 To date, KAL1mutations
cause only KS,2 whereas GNRHRmutations are restricted to
normosmic IHH.14 Only mutations in FGFR1 are known to
cause both normosmic IHH and KS.
Heterozygous CHD7 (chromodomain helicase DNA-
bindingprotein7,MIM608892)mutationshavebeen iden-
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Figure 1. CHD7 Domains and Positions of Mutations
CHD7 structure with functional domains and the positions of five missense mutations and two splice-donor site mutations identified in
IHH and KS patients are shown. The following abbreviations are used: chrom1, chromodomain 1; chrom2, chromodomain 2; SANT, SANT
DNA binding domain; and LZD, leucine zipper domain. The function of CR1-CR3 and BRK domains are unknown. Three mutations affect
chromodomains. Relative sizes and locations of domains are to scale.(MIM 214800), a multisystem autosomal-dominant or spo-
radic disorder consisting of eye coloboma, heart defects,
choanal atresia, retardation of growth and development,
genito-urinary anomalies, and ear abnormalities (vestibular
and auditory).15 The large 2997 amino acid (AA)CHD7 pro-
tein contains two chromodomains at its N terminus, fol-
lowed by centrally located SNF2 and helicase domains;
three conserved region (CR) domains; a switching-defective
protein3, adaptor 2, nuclear receptor corepressor, transcrip-
tion factor IIIB (SANT) domain; two Brahma and Kismet
(BRK) domains; and, at the C terminus, a leucine-zipper
domain, which we identiﬁed by using PSORTII prediction
software (Figure 1A). The leucine-zipper domain is located
in AA 2888–2909 (LAFNPFLLSTMAPGLFYPSMFL). CHD7
belongs to a family of nine CHD proteins that have in com-
mon the ability to utilize ATP hydrolysis to alter nucleo-
some structure.16 Chromodomains have been thought to
mediate chromatin interactions and have been found to
interact with DNA, RNA, and histone targets.17
CHD7 is expressed in the disease-associated organs of
CHARGE syndrome, but also in KS-relevant tissues includ-
ing the olfactory epithelium18 and pituitary19 in mice, as
well as the olfactory nerve and bulb, hypothalamus, and
pituitary in humans.20 Prior to the identiﬁcation of
CHD7, hypogonadism was reported to be associated with
CHARGE syndrome, including some patients old enough
to be diagnosed with IHH, as deﬁned below.21 Several other
studies implicate a possible connection between the KS
phenotype and CHARGE syndrome, although it is impor-
tant to emphasize that these patients with CHARGE syn-
drome are not yet of pubertal age. Anosmia or hyposmia
has been identiﬁed in children with CHARGE syndrome,22
as well abnormal olfactory bulbs by magnetic resonance
imaging (MRI).23 Most boys studied had micropenis and/
or cryptorchidism suggestive of IHH, although all subjects
were prepubertal.23 None of seven females under 12 years
of age began puberty spontaneously, and hormonal data512 The American Journal of Human Genetics 83, 511–519, Octobersuggested that IHH could ensue as they got older.23 In
fact, recently one female with CHARGE syndrome due to
a CHD7 mutation and with some features of KS has been
reported.24 However, there has been no systematic evalua-
tion of IHH/KS patients without a diagnosis of CHARGE
syndrome for the presence of CHD7 mutations. We
hypothesized that IHH/KS could be a milder allelic variant
of CHARGE syndrome.
We ﬁrst looked at Chd7mRNA expression in three differ-
ent mouse GnRH neuronal cell lines, twomigratory (GN11
and NLT)25 and one postmigratory (GT1-7).26 Chd7-mRNA
expression was conﬁrmed by cloning and sequencing of
the PCR products (not shown). Next, RT-PCR on RNA
extracted from KS-relevant rat tissues demonstrated ex-
pression in the olfactory bulb, medial basal hypothalamus,
and pituitary (Figure S1 available online). Therefore, we
undertook an extensive mutation analysis in IHH/KS
patients without clinical features of CHARGE syndrome.
IHH was deﬁned as the absence of puberty in femalesR
17 yr old and in malesR 18 yr old with low serum gonad-
otropins as described previously.1 Males had low serum
testosterone (<100 ng/dL, with normal being 300–1100),
and females had hypoestrogenic amenorrhea, and remain-
ing pituitary function and CNS imaging byMRI or CTwere
normal.1 KS was deﬁned as IHH and anosmia or hyposmia,
as detailed by the University of Pennsylvania Smell Identi-
ﬁcation Test when possible or by patient history. This
study was approved by the Human Assurance Committee
(Medical College of Georgia), and signed written consent
was obtained from all participants. Previously, mutation
screening was performed in most patients for KAL1,
GNRHR, and FGFR1 genes.14,27–30
DNA sequencing of the entire 37 protein-coding exons
and splice junctions of the CHD7 gene from 101 affected
individuals (50 with KS and 51 with normosmic IHH)
revealed six heterozygous mutations—one splice-donor
site alteration and ﬁvemissense mutations for a prevalence10, 2008
Table 1. CHD7 Mutations in Sporadic Patients with IHH/KS
Patient Gender and Phenotype Geographic Origin Exon or Intron Nucleotide Change Amino Acid Change Confirmatory Method
TT20 Male, IHH; no other
anomalies
Turkey Intron 8 IVS8þ5G/A Premature termination 0/180 controls & 0/96
Turkish controls
C187 Female, KS, cleft lip and
palate, hearing loss
USA Intron 6 IVS6þ5G/C 22 amino acid deletion De novo, 0/180 controls,
and 0/96 Turkish controls
C59 Male, IHH and cleft lip;
cryptorchidism
USA Exon 8 c.2501C/T Ser834Phe 0/180 controls
C148 Male, KS; no other
anomalies
USA Exon 2 c.164A/G His55Arg 0/180 controls
T47 Male, IHH, myopia; no
other anomalies
Turkey Exon 38 c.8365G/A Ala2789Thr 0/180 controls and 0/96
Turkish controls
C137 Male, IHH; cryptorchidism USA Exon 38 c.8639C/T Pro2880Leu 0/180 controls and 0/96
Turkish controls
C26 Male, KS; no other
anomalies
USA Exon 38 c.8842A/G Lys2948Glu 0/180 controlsof 6% (Table 1; Figures 1 and 2; Figure S2). Another hetero-
zygous splice-donor site mutation was identiﬁed in one of
96 additional IHH/KS patients screened for mutations only
in exons 6–10. This gene region was selected for a focused
mutation screen because these exons encode the highly
conserved and important functional chromodomains (Fig-
ure 1). All cases with mutations were sporadic, and none of
the probands had any affected family members or relatives.
No identical nucleotide changes were identiﬁed in 180 con-
trols or listed in the single-nucleotide polymorphism (SNP)
database. In addition, the two CHD7 mutations identiﬁed
in probands of Turkish descent were also absent in 96 Turk-
ish controls. Six new SNPs (Table S1, submitted into the
SNP database in NCBI) in the CHD7 were also detected.
None of the patients with a CHD7 mutation were known
to possess a mutation in another gene involved in IHH/KS.
Both intronic mutations impaired mRNA splicing in
lymphoblasts of affected individuals and are predicted to
interfere with protein function. An IVS8þ5G/Amutation
identiﬁed in a normosmic IHH male without any other
anomalies resulted in exon 8 skipping, as determined by
RT-PCR of CHD7 exons 4–10 from patient and control
lymphoblastoid RNA, subsequent subcloning, and DNA
sequencing. This mutant introduces 16 aberrant out-of-
frame AA residues, causing a frameshift and subsequent
premature termination codon at residue 849 located 49 bp
downstream of the junction of exons 7 and 9. This re-
sults in a CHD7 protein predicted to be truncated more
than 70% of the C terminus (Figure 2A). This transcript
is not a normal splice variant because it was absent in
four control lymphoblastoid cell lines, and nor was the
same G/A transition identiﬁed in 180 normal controls.
Importantly, this mutation removes about half of the ﬁrst
and all of the second chromodomains, as well as other
important domains of the protein, thereby predicting a
nonfunctional protein.
In a KS female withmild sensorineural deafness and cleft
lip and palate, a de novo heterozygous intronic transver-
sion, IVS6þ5G/C, was identiﬁed. The mutation was
absent in both parents. For direct examination of whetherThe Americthis variant affects splicing, CHD7 exons 4–9 were similarly
analyzed by RT-PCR. In addition to the normally spliced
transcript, a transcript with reduced size demonstrated
exon 6 skipping not observed in four controls (Figure 2B).
This results in an in-frame deletion of 22 of 66 AAs of
chromodomain 1. Chromodomains are evolutionarily
conserved16 and known to interact with histone tails.31,32
Interestingly, this mutation has also been reported in a
patient with CHARGE syndrome.33 The patient with
CHARGE syndrome has additional severe phenotypic ﬁnd-
ings, including the absence of earlobes, triangular concha,
vestibular disturbance, autism-spectrum disorder, and
mental retardation,33 which are absent in our KS patient.
The ﬁve missense mutations affect highly conserved AA
residues when compared with known CHD7 orthologs
(Figure 3A). Four of ﬁve point mutations were predicted
to be deleterious by SIFT34 (Ser834Phe, Lys2948Glu,
Pro2880Leu, and His55Arg), whereas Ala2789Thr was
tolerated. Ser834Phe, located in DNA-binding chromodo-
main 1 (UniProtKB/Swiss-Prot entry Q9P2D1; INTERPRO
IPR000953),35,36 a highly conserved sequence motif ob-
served in a variety of animal and plant species, had the
highest conﬁdence measure. Further supportive evidence
of the deleterious effect of Ser834Phe comes from the
report of the samemutation in three patients from a family
with a severe CHARGE syndrome phenotype.37
Structural models for the relevant domains suggest that
Ala2789Thr and Pro2880Leu, located in the spacer se-
quence between the BRK2 and leucine-zipper regions, as
well as Lys2948Glu, are also detrimental. All three AA res-
idues are located in loop regions so that mutations of these
residues will most likely affect structural and binding prop-
erties of the domains to their interaction partners (Figures
3B1 and 3B2). The local secondary structure of the region
around Pro2880 is a random coil, and the Pro2880Leu
mutation induces helix formation in this region, predict-
ing its deleterious effect (data not shown). The Ser834 res-
idue is also located in a loop region, coordinating strongly
with adjacent residues in the neighboring helix (Tyr881,
context PDYV), so Phe834 will therefore strongly affectan Journal of Human Genetics 83, 511–519, October 10, 2008 513
Figure 2. CHD7 Exon Skipping in Two
Patients
(A) RT-PCR analysis of CHD7 exon-skipping
event in a patient with IVS8þ5G/A RT-
PCR analysis confirms that the
IVS8þ5G/A mutation of CHD7 causes
aberrant exon 8 skipping in an IHH
patient. Splicing patterns are compared
between a normal control and the mutant
by cloned cDNA sequencing. An expected
CHD7 product of 565 bp consisting of exons
4–10 is observed in the control (lane 2),
whereas an abnormal product of 450 bp
skipping exon 8 (115 bp) is observed in
a patient with IVS8þ5G/A (lane 3).
Exon 9 nucleotide and out-of-frame AA
sequence are depicted in blue. A 123 bp
DNA marker is shown in the first lane.
The aberrant exclusion of exon 8 (115 bp)
in a patient with IVS8þ5G/A is predicted
to introduce a frameshift in the coding re-
gion and a subsequent premature termina-
tion codon at 16 AAs downstream from
exon 8 skipping. In the truncated CHD7,
16 out-of-frame AA residues generated by
the frameshift are depicted as a black bar
at the end. The functional domains from
N terminus to C terminus are depicted in
color as follows: orange, chromodomains
1 and 2; navy blue, SNF2; sky blue, heli-
case; green, CR1, CR2, and CR3; deep
green, BRK1 and BRK2; and red, leucine
zipper domain. The SANT domain within
CR3 was not depicted here.
(B) RT-PCR analysis of CHD7 exon skipping
event in a patient with IVS6þ5G/C RT-
PCR analysis shows that mutation
IVS6þ5G/C of CHD7 causes aberrant
exon 6 skipping in a KS patient. Splicing
patterns are compared between a normal
control and the mutant by cloned cDNA se-
quencing. An expected CHD7 product of
576 bp consisting of exons 4–9 is observed
in the control (lane 2), whereas an abnor-
mal product of 510 bp skipping exon 6
(66 bp) is observed in a patient with
IVS6þ5G/C (lane 3). A 1 kb DNA marker
is shown in the first lane.
The abnormal exon 6 (66 bp) skipping in a
patient with IVS6þ5G/C causes a 66 bp
in-frame deletion of 22 AAs. From chromo-
domain 1 comprising 66 AAs, 16 residues
are deleted. Protein structure of the de-
leted region is depicted in yellow and chro-
modomains 1 and 2 in orange.protein stability (Figure 3B3). The Ala2789T residue is
conserved in seven of eight orthologs, and Lys2948 is rela-
tively conserved (Figure 3A).
SIFT was also used to characterize the functional signiﬁ-
cance of a 22 amino acid (ESVDAEGPVVEKIMSSRSVKKQ)514 The American Journal of Human Genetics 83, 511–519, Octoberin-frame deletion of exon 6 (IVS6þ5G/C mutant) by
predicting deleterious effects for almost all possible AA
substitutions in this region (data not shown). The splice
mutant IVS8þ5G/A truncates the functional part of the
protein starting at AA 810, including the region from AAs10, 2008
920–1490. The latter is highly homologous to the SWI2/
SNF2 chromatin-remodeling domain of eukaryotic Rad54
(PDB code: 1Z3I)38 and therefore an essential DNA-binding
domain of the wild-type. Collectively, involvement of the
conserved chromodomain by three mutations, two of
which have been identiﬁed in patients with CHARGE syn-
drome,33,37 as well as SIFT AA conservation and protein
structural analysis, indicates that these nucleotide alter-
ations are pathogenic mutations.
To investigate developmental expression of Chd7 further
in the mouse embryo, in situ hybridization analysis was
performed from embryonic day 10.5 (E10.5) to postnatal
day 0 (P0). Already by E10.5 and E11, high Chd7 expres-
sion was preferentially observed in the developing nervous
system and its derivatives. The entire neuroepithelium was
strongly labeled at that stage (Figures 4A–4C). At E10.5
and E11, high levels of expression were particularly note-
worthy in the olfactory placode (Figures 4A and 4C), which
gives rise to olfactory and GnRH neurons. With progress-
ing differentiation, the label intensity declined and the
signal became restricted to speciﬁc locations in the devel-
oping central and peripheral nervous systems. At E14,
high signal intensity was seen in the olfactory epithelium,
cochlea, anterior pituitary, and the spinal cord (Figures 4D
and 4E). This pattern of expression is consistent with
involvement of Chd7 in the development of the olfactory
pathway and the GnRH-positive neurons.39 In the adult
brain, intense Chd7 expression was restricted to the
granule cell layer of the cerebellum (Figure 4H), hippocam-
pal formation (Figure 4I), and hypothalamus (Figures 4F
and 4G). Signals were absent when the sense control was
used.
The molecular basis for 70%–75% of IHH/KS patients
remains unknown.2 To date, only FGFR1 mutations have
been reported to cause either normosmic IHH families or
KS families.7 Although a homozygous PROKR2 deletion
was seen in a single family comprising both normosmic
and anosmic patients, this represents variable expressivity
within the same family.40 In our case, we have three unre-
lated probands with KS and four unrelated probands with
IHH with CHD7 mutations, demonstrating that CHD7 is
involved in either IHH or KS. We present new evidence
for a role of CHD7 in the pathophysiology of both normos-
mic IHH and KS patients without a CHARGE phenotype.
We ﬁrst demonstrate Chd7 mRNA expression in both
migratory and postmigratory GnRH neuronal cell lines.
We also document mRNA expression in the hypothala-
mus, pituitary, and olfactory bulb in the rat—all of which
are IHH/KS-relevant organs. By in situ hybridization, we
conﬁrm mRNA expression at the appropriate time when
GnRH and olfactory neurons migrate from the olfactory
placode region to the hypothalamus. This begins on
E10–E11 in the mouse and is virtually completed by
E18.5.39 In humans, GnRH migration begins at E5.5–E6.5
weeks and ﬁnishes 6–8 weeks postnatally.39 Whether or
not CHD7 affects this important developmental neuron
migration requires future study.The AmeriFurthermore, we demonstrate sporadic heterozygous
CHD7 mutations, which were not present in R 180 con-
trols or the SNP database, in humans with both normosmic
IHH and anosmic IHH (KS). Additionally, twomutations in
Turkish patients were also absent in 96 Turkish controls
(for a total of 276 controls). The prevalence of CHD7muta-
tions of ~6% is similar to that of apparently sporadic KAL1
mutations2 and somewhat less than the 10% reported rate
of FGFR1 mutations in IHH/KS.7 Two of our CHD7 muta-
tions alter mRNA splicing in lymphoblast RNA and predict
deletions of chromodomains, whereas another missense
mutation within chromodomain 1 affects a highly con-
served Ser residue. The disruption of these important
evolutionarily conserved chromodomains is highly likely
to result in deleterious consequences,16 because chromo-
domains are known to interact with histone tails.31,32
Chromodomain deletion has also been reported to impair
nucleosome binding and remodeling by CHD proteins,41
indicating that their disruption will be detrimental to
CHD7 function.
Further supportive evidence that our CHD7 mutations
are deleterious comes from SIFT analysis, which indicates
that four of the ﬁve missense mutations (Ser834Phe,
Lys2948Glu, Pro2880Leu, and His55Arg) involve highly
conserved AA residues among known species and, there-
fore, are not likely to be tolerated by their observed
substitutions.34 These ﬁndings were also corroborated by
protein structural analysis of the AA variants Ala2789Thr,
Pro2880Leu, and Lys2948Glu, which were predicted to al-
ter structural and binding properties of the domains. Taken
together, both AA conservation and protein structural
modeling provide additional support that these missense
substitutions are highly likely to be deleterious mutations.
Importantly, our one IHH and one KS patient, who both
lack the CHARGE phenotype, possess the same mutations
(Ser834Phe and IVS6þ5G/C) reported previously in pa-
tients with CHARGE syndrome,33,37 further demonstrat-
ing the allelic relationship of both syndromes. The KS pa-
tient with the IVS6þ5G/C mutation does not fulﬁll
Blake’s criteria for CHARGE syndrome,42 although she
does have hearing impairment and cleft lip and palate.
This also indicates that the effects of modifying genes
may determine whether the patient has the more severe
CHARGE phenotype rather than the milder IHH/KS phe-
notype. Interestingly, our mutations have been localized
to regions around four exons—2, 6, 8, and 38—suggesting
the possibility of hotspots for IHH/KSmutation. Because of
these ﬁndings and the absence of nonsense mutations,
which often occur in CHARGE syndrome,15 we provide
the ﬁrst convincing evidence that IHH/KS represents
a milder allelic variant of CHARGE syndrome. Although
its precise function is uncertain, CHD7 appears to be im-
portant in GnRH and olfactory neuron migration to their
embryologic destination in the hypothalamus. CHD7 is
the ﬁrst chromatin-remodeling protein involved in normal
puberty in humans and is the second gene (after FGFR1)
identiﬁed that results in both normosmic IHH and KS.can Journal of Human Genetics 83, 511–519, October 10, 2008 515
Figure 3. Protein Sequence Alignment and Structure Modeling of CHD7
(A) Multiple protein-sequence alignment of CHD7 with its orthologs. The positions of residues affected by missense mutations in IHH/KS
patients are marked by asterisks and bold letters in available CHD7 animal orthologs. H55 and S834 are evolutionarily fully conserved,
whereas A2789 and P2880 are highly conserved. K2948 shows relative conservation. Human CHD7 N-terminal residues 1–1423 are missing
in the predicted rat Chd7 protein (NP_001101376). Blue shading represents the invariant residues that match the consensus exactly, and
pink shading shows partial matching.
(B) CHD7 structure modeling.
(B1 and B2) Shown are alternate views of the model of the 300 AA C-terminal region of CHD7 based on the 3DJURY model, which results
from the alignment of this region with that of mdia1 gbd-fh3 in complex with rhoc (1z2c/B). Regions of the model that were predicted
solely on the basis of homology in 3DJURY are shown in green, but additional information was used to substantiate the model. There is an
additional long consecutive region where EMBOSS found substantial sequence similarity to the CHD7 sequence—these regions are marked
in dark blue. Regions that, in addition to the alignment, agree in their secondary structure with the consensus prediction of PHYRE are
shown in light brown. Finally, we found a region that, in addition to the alignment and secondary structure, exhibits a motif commen-
surate with the leucine zipper (bright blue). Sites and side chains of the three mutations Lys2948Glu, Pro2880Leu, and Ala2789Thr are
shown in red for better visibility. All mutation sites lie in highly flexible loop regions. (B1) and (B2) show the same model rotated 180

around the vertical axis though the center of the molecule.
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Figure 4. Chd7 Expression during Murine Development
The following abbreviations are used: OP, olfactory placode; GCL, granule cell layer of the cerebellum; OE, olfactory epithelium; aPG,
anterior pituitary gland; pPG, posterior pituitary gland; SC, spinal cord; CA1, CA1 region of the hippocampus; CA3, CA3 region of the
hippocampus; DG, dentate gyrus; CO, cochlea; E, eye; and NP, nasal pit.
(A) DIG-labeled whole-mount in situ hybridization using a Chd7 antisense probe shows high expression in the olfactory placode at E10.5.
(B and C) Strong labeling of neuroepithelial structures is seen at E11, shown in higher magnification in (C).
(D and E) Expression of Chd7 in the olfactory epithelium, developing cortex, cochlea, spinal cord, and anterior pituitary gland at E14.
[35S]-UTP-labeled in situ hybridizations are shown in (E). Inset shows magnification of the pituitary gland.
(F–I) Expression of Chd7 in the adult brain: Singular DIG-positive cells are found scattered within hypothalamic nuclei of the
preoptic area (F). One cluster of cells within the medial preoptic area consistently stained positively for Chd7 (G). DIG-labeled
in situ hybridizations on 12 mm cryosections show expression in the cerebellum (H). The inset in (H) shows an overview of the
adult brain with a [35S]-UTP labeled Chd7 antisense probe. The hippocampal region also stains positive for Chd7 (I).Supplemental Data
Supplemental Data include two ﬁgures and two tables and can be
found with this article online at http://www.ajhg.org/.
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